4.3 Functional Magnetic Resonance Spectroscopy in Patients With Schizophrenia

Background: There has been considerable interest in the role of glutamatergic neurotransmission in schizophrenia, with elevations in medial prefrontal glutamine being reported in the early phase of the illness. In contrast, in patients with chronic schizophrenia, reduced levels of glutamine and glutamate have been reported. These reductions may represent reductions in glutamatergic neurotransmission or loss of neuronal density or synaptic...